We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Siemens Exhibits Intelligent and Integrated Portfolio of IVD Solutions at AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 27 Sep 2021

Siemens Healthineers (Erlangen, Germany) exhibited its intelligent, integrated range of IVD solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held in Atlanta on September 26-30. More...

AACC's annual meeting is the world's largest lab medicine conference with nearly 20,000 participants from more than 100 countries. At this year’s AACC, Siemens highlighted its Atellica Solution range of flexible, scalable, automation-ready immunoassay and chemistry analyzers. The Atellica Solution is comprised of sample management, as well as immunoassay and chemistry analyzers, and is an excellent fit for mid-and high-volume labs. It delivers unprecedented flexibility to adapt to changing testing needs and space constraints. The company demonstrated how its Atellica Integrated Automation (AIA) on the Atellica Solution consolidated revolutionary sample management technology, intelligent software, and IT to provide workflow efficiency with the flexibility to add decapping with little or no additional footprint.

Siemens also demonstrated its new, more-scalable automation solutions that include pre- and post-analytics for labs of all sizes to accommodate their specific needs, testing volumes, and resources. Siemens showed how labs could achieve open, one-touch, end-to-end testing with Aptio Automation; Drive open, one-touch sample preparation for multidisciplinary labs with its Atellica Task Targeted Automation; and streamline lab’s biggest chemistry and immunoassay workloads with the Atellica Integrated Automation

Siemens also introduced its new Atellica Hematology Portfolio that pairs analyzers and automation with intelligence to streamline operations and support accurate clinical decision-making that’s on-time, every time. The company displayed two new flagship hematology analyzers - Atellica HEMA 570 and 580 – that are designed to deliver reliable performance targeted for high volume routine workloads.

Siemens is currently developing the Atellica CI 1900 System for the lower-to-mid-volume laboratories. It is planned to utilize the same menu, reagents, consumables, and detection technology as the Atellica Solution2. The Atellica CI 1900 System1 is being designed to take the lab a step beyond by offering the same workflow and IT across the network with the goal of redefining standardization.

Related Links:
Siemens Healthineers


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Platelet Function Analyzer
AGGRENG-40
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.